Savara Inc.
Clinical trials sponsored by Savara Inc., explained in plain language.
-
New hope for kids with rare lung condition: inhaled protein therapy in trial
Disease control Recruiting nowThis study tests an inhaled drug called molgramostim in children aged 6 to 18 with autoimmune pulmonary alveolar proteinosis (aPAP), a rare disease where protein builds up in the lungs and makes breathing hard. All 5 participants will take the drug daily via a nebulizer for 12 mo…
Phase: PHASE3 • Sponsor: Savara Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New hope for rare lung disease: investigational drug now available through expanded access
Disease control AVAILABLEThis program offers adults with autoimmune pulmonary alveolar proteinosis (aPAP) access to an investigational inhaled medication called molgramostim. aPAP is a rare lung condition where surfactant builds up, making breathing difficult. The drug aims to help the lungs clear this b…
Sponsor: Savara Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC